Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).
暂无分享,去创建一个
T. Tammela | A. Snapir | T. Sarapohja | K. Fizazi | N. Shore | Matthew R. Smith | A. Mohamed | I. Kuss | D. Odom | J. Bartsch | Marie-Aude Le Berre | M. Berre